Similar Search Results

Narrow search

New estimates of drug development costs

Frank, Richard G. - In: Journal of Health Economics 22 (2003) 2, pp. 325-330

Persistent link: https://www.econbiz.de/10005052948

Custom-made versus ready-to-wear treatments: Behavioral propensities in physicians' choices

Frank, Richard G.; Zeckhauser, Richard J. - In: Journal of Health Economics 26 (2007) 6, pp. 1101-1127

Persistent link: https://www.econbiz.de/10005123079

The decision to seek an exemption from PPS

Lave, Judith R.; Frank, Richard G.; Rupp, Agnes; Taube, Carl - In: Journal of Health Economics 7 (1988) 2, pp. 165-171

Persistent link: https://www.econbiz.de/10005293374

Measuring adverse selection in managed health care

Frank, Richard G.; Glazer, Jacob; McGuire, Thomas G. - In: Journal of Health Economics 19 (2000) 6, pp. 829-854

Persistent link: https://www.econbiz.de/10005293403

In recognition of Joseph P. Newhouse

Frank, Richard G.; McGuire, Thomas G. - In: Journal of Health Economics 26 (2007) 6, pp. 1071-1072

Persistent link: https://www.econbiz.de/10005293453

Economic rents derived from hospital privileges in the market for podiatric services

Frank, Richard G.; Weiner, Jonathan P.; Steinwachs, … - In: Journal of Health Economics 6 (1987) 4, pp. 319-337

Persistent link: https://www.econbiz.de/10005204458

Price regulation and relative delays in generic drug adoption

Costa-Font, Joan; McGuire, Alistair; Varol, Nebibe - In: Journal of Health Economics 38 (2014) C, pp. 1-9

Increasing the adoption of generic drugs has the potential to improve static efficiency in a health system without harming pharmaceutical innovation. However, very little is known about the timing of generic adoption and diffusion. No prior study has empirically examined the differential launch...

Persistent link: https://www.econbiz.de/10011117216